The use of dipeptidyl peptidase-4 inhibitors has recently been found to be associated with inflammatory bowel disease in patients with type 2 diabetes. Using prescribing data from 700 general practices in the UK, researchers observed that during 552 413 person years of follow-up, 208 incident inflammatory bowel disease events occurred – use of dipeptidyl peptidase-4 inhibitors was associated with an increased risk of inflammatory bowel disease (53.4 v 34.5 per 100 000 person years; hazard ratio 1.75, 95% confidence interval 1.22 to 2.49). The hazard ratios gradually increased with longer use, peaking after three to four years of use (hazard ratio 2.90, 1.31 to 6.41) and decreasing thereafter. Read more at